Related Experiment Video
Updated: Jun 10, 2025

Single-stage Dynamic Reanimation of the Smile in Irreversible Facial Paralysis by Free Functional Muscle Transfer
Published on: March 1, 2015
Rapid Resolution of Delayed Facial Palsy in Miller Fisher Syndrome With Steroid Therapy
Nithisha Thatikonda1, Alexandru Lerint1, Vijaya Valaparla1
1Department of Neurology, University of Texas Medical Branch Galveston, Galveston, TX 77550, USA.
Abstract:
Miller Fisher syndrome (MFS), a variant of Guillain-Barre syndrome (GBS), is characterized by the classic triad of ataxia, areflexia, and ophthalmoplegia. Approximately 20% of MFS patients experience facial weakness, with a subset developing delayed facial palsy (DFP) after other neurological symptoms have peaked or begun to improve. Initially, DFP was considered a natural progression of MFS, leading to recommendations against additional treatment. However, DFP persisted for more than 50 days without additional treatment in some patients, prompting additional steroid therapy, resulting in quicker resolution of DFP. We describe an MFS patient who presented with the classic triad of MFS and subsequently developed DFP. The patient was treated with methylprednisolone pulse therapy (1,000 mg/day for 3 days) followed by oral prednisolone (60 mg/day) with a gradual taper, resulting in rapid and complete resolution of DFP, suggesting an alternative mechanism behind DFP, opening avenues for further research and insights into this matter. MFS-DFP is rarely reported in the literature. In addition to this case, we aim to provide a comprehensive literature review on MFS-DFP, to further expand the existing knowledge on the current concepts of DFP-MFS.
More Related Videos
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Skeletal Muscle Relaxants: Therapeutic Uses
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Psychosis: Goals of Pharmacotherapy
Myocarditis III: Medical Management
Skeletal Muscle Relaxants: Adverse Effects
Unlike...

